{"task_id": "4322caf3de61ec2d", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 72/464)", "text": "ATORY BLOOD PRESSURE MONITOR\n\u0002 ECG\nHypertension\n57\n\n--- Page 79 ---\nINVESTIGATIONS (CONT\u2019D)\nSECONDARY CAUSES WORKUP\n\u0002\nENDOCRINE WORKUP\nCa, albumin, TSH, serum\nrenin/aldosterone, cortisol, 24 h urine meta\nnephrine and creatinine, serum osmolality,\nurine osmolality, urine lytes, selective adrenal\nvein sampling\n\u0002\nRENAL ARTERY STENOSIS WORKUP\nrenal dopplers,\ncaptopril renogram, CT/MR angiogram, renal\nangiogram\n\u0002\nSLEEP OXIMETRY TEST\nif suspect sleep apnea\nDIAGNOSTIC ISSUES\nCLINICAL DIAGNOSIS OF HYPERTENSION\n1. Hypertensive urgency or emergency during\nfirst visit?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=proceed to step 2\n2. What is blood pressure during second visit?\n\u0002 BP \u0005180/110 mmHg=hypertension diagnosed\n\u0002 BP 140 179/90 109 mmHg=proceed to step 3\n\u0002 BP <140/90 mmHg=continued follow up\n3. Target organ damage, diabetes, or chronic\nkidney disease?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=proceed to step 4 for clinic patient, step 6\nfor ambulatory BP monitoring, or step 7 for\nhome BP monitoring\n4. BP \u2021160/100 mmHg during third visit?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=consider ambulatory BP monitoring (step\n6) or proceed to step 5\n5. BP \u2021140/90 mmHg during fourth or fifth visit?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=continue follow up\n6. Ambulatory BP monitoring: mean awake BP\n\u2021135/85 mmHg OR mean 24 h BP \u2021130/\n80 mmHg?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=continue followup\n7. Home BP monitoring: average BP \u2021135/\n85 mmHg?\n\u0002 Yes=hypertension diagnosed\n\u0002 No=continue follow up or proceed to ambula\ntory BP monitoring (step 6)\nCHEP Guidelines 2009\nhttp://www.hypertension.ca\nACUTE MANAGEMENT\nACUTE\nABC, O2, IV\nHYPERTENSIVE EMERGENCY\nlabetalol 20 mg IV\nbolus initially, then 20 80 mg q10min, or 2 mg/min\nIV infusion (loading) then 2 8 mg/min, maximum\ntotal dose of 300 mg. Nitroprusside 0.25 0.5 mg/kg/\nmin IV initially, increase by 0.5 mg/kg/min increments,\nACUTE MANAGEMENT (CONT\u2019D)\nto usually target 3 mg/kg/min (rarely >4 mg/kg/min,\nmaximum 10 mg/kg/min). Nicardipine 5 mg/hr IV initi\nally, titrate to a maximum of 15 mg/hr. Fenoldopam\n0.1 mg/kg/min IV initially, titrate dose q15min. Con\nsider ICU admission. Workup and treatment of under\nlying causes once stabilized\nHYPERTENSIVE URGENCY\nfurosemide 20 40 mg\nPO/IV \u00041 dose. Nifedipine 0.25 0.5 mg/kg PO\nq4 6h. Clonidine 0.1 0.3 mg PO BID. Captopril\n25 50 mg PO TID. Labetalol 5 20 mg IV q15min or\nhydralazine 5 20 mg IV q15min to keep SBP\n<170 mmHg. Workup and treatment of underlying\ncause once stabilized\nLONG TERM MANAGEMENT\nLIFESTYLE CHANGES\nhealthy diet (high in fresh\nfruits, vegetables, and low fat dairy products; low in\nsaturated fat and salt <100 mmol/day). Physical\nactivity (optimum 30 60 min of moderate cardiopul\nmonary activity 4 7\u0004/week). Reduction in alcohol\n(<2 drinks/day in men and <1 drink/day in women).\nWeight loss (in those with BMI >25 kg/m2, lose\n>5 kg). Smoke free environment\nANTIHYPERTENSIVES wABCDw\n\u0002 ACE INHIBITOR\nramipril 2.5 10 mg PO daily BID,\ncaptopril 12.5 50 mg PO TID, perindopril 2 8 mg\nPO daily, lisinopril 2.5 10 mg PO daily\n\u0002 ARB\ncandesartan 8 32 mg PO daily, losartan\n50 100 mg PO daily\n\u0002 b-BLOCKERS\nno longer first line agent for age\n>60.\nMetoprolol\n50 100\nmg\nBID,\natenolol\n50 100 mg PO daily, labetalol 100 400 mg PO\nTID, bisoprolol 5 10 mg PO daily\n\u0002\nCALCIUM CHANNEL BLOCKERS\namlodipine 2.5 10 mg\nPO daily, diltiazem CD 180 360 mg PO daily\n\u0002\nDIURETICS\nhydrochlorothiazide 12.5 25 mg PO\ndaily, chlorthalidone 25 mg PO daily, spironolac\ntone 12.5 50 mg PO daily\n\u0002 a1 AGONISTS\nclonidine 0.1 0.5 mg PO BID, tera\nzosin 1 20 mg PO daily\n\u0002\nOTHERS\nminoxidil, phentolamine, hydralazine\nTREAT UNDERLYING CAUSE\nrenal artery steno\nsis (angioplasty with stenting, nephrectomy of\natrophic kidney \u0007 endarterectomy)\nTREATMENT ISSUES\nACE INHIBITORS/ANGIOTENSIN RECEPTOR\nBLOCKERS\n\u0002\nINDICATIONS\nHF, post MI, diabetes, proteinuria,\nrenal failure (with caution), LVH\n\u0002\nCONTRAINDICATIONS\npregnancy,\nESRD,\nbilateral\nRAS\n\u0002\nADVERSE EFFECTS\ncough (less with ARB), angioe\ndema, hyperkalemia\n58\nHypertension", "text_length": 3972, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 72/464)", "type": "chunk", "chunk_index": 71, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.335052", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.335788", "status": "complete", "chunks_added": 3}